Honasa Consumer has terminated its plan to acquire a 58% stake in Fluence Pharma after failing to meet agreed closing conditions. The deal, announced in June at a ₹135 crore valuation, was intended to boost the company's presence in the nutraceuticals market. Despite the cancellation, the company confirmed that its strategy to expand in this category remains unchanged.
Honasa Consumer, the parent company of the Mamaearth brand, has officially stopped its planned acquisition of a majority stake in the nutraceuticals firm Fluence Pharma. The company informed the stock exchanges on Tuesday that it would not proceed with the deal to acquire a 58% shareholding in the business. This decision follows the failure to fulfill certain closing conditions that were set out in the initial share purchase agreement.
The transaction, which was first announced to the public on June 23, 2026, was valued at an enterprise value of approximately ₹135 crore. Under the original plan, this acquisition was expected to be a key step for Honasa to expand its footprint in the health and wellness product segment. However, the company noted that the critical conditions required for the deal to close were not satisfied, leading to the termination of the agreement.
Strategic Focus on Nutraceuticals
While the Fluence Pharma acquisition has been called off, Honasa Consumer has signaled that its long-term goals for the nutraceuticals sector remain intact. The company recently established a dedicated subsidiary, Honasa Health, which is designed to lead its initiatives in the wellness and health space. Management indicated that the business will continue to explore other options, including both developing its own products and identifying new potential acquisitions, to build a stronger portfolio in this market.
From a financial perspective, Honasa Consumer enters this period with a stable balance sheet. In its recently reported results for the first quarter of the 2027 fiscal year, the company posted a net profit of ₹90.4 crore, marking a 119% growth compared to the same period in the previous year. This performance, along with a consolidated revenue of ₹756 crore for the quarter, provides the company with the financial flexibility to continue its expansion efforts despite the collapse of this specific deal.
What Investors May Track
For investors and market participants, the termination of this deal highlights the challenges that can arise during the final stages of corporate transactions, particularly when conditions precedent—the agreed-upon requirements for completing a merger or acquisition—are not met. The company has not provided specific details on which conditions remained unfulfilled, which is standard in such regulatory filings. The key area to monitor in the coming quarters will be how Honasa Consumer plans to replace this planned acquisition. Investors may look for updates on the progress of its Honasa Health subsidiary and whether the company shifts its focus toward developing its own internal health brands or targets other companies to achieve its growth objectives in the competitive wellness sector.